מירסרה 360 מקג0.6 מל ישראל - עברית - Ministry of Health

מירסרה 360 מקג0.6 מל

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta - תמיסה להזרקה - methoxy polyethylene glycol-epoetin beta 360 mcg / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic kidney disease (ckd).

אקסטביה ישראל - עברית - Ministry of Health

אקסטביה

novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm

קארזיבה ישראל - עברית - Ministry of Health

קארזיבה

medison pharma ltd - dinutuximab beta - תרכיז להכנת תמיסה לאינפוזיה - dinutuximab beta 4.5 mg / 1 ml - dinutuximab

פלגרידי 125 ישראל - עברית - Ministry of Health

פלגרידי 125

medison pharma ltd - peginterferon beta 1a - תמיסה להזרקה - peginterferon beta 1a 125 mcg / 0.5 ml - peginterferon beta-1a

פלגרידי 63 ישראל - עברית - Ministry of Health

פלגרידי 63

medison pharma ltd - peginterferon beta 1a - תמיסה להזרקה - peginterferon beta 1a 63 mcg / 0.5 ml - peginterferon beta-1a

פלגרידי 94 ישראל - עברית - Ministry of Health

פלגרידי 94

medison pharma ltd - peginterferon beta 1a - תמיסה להזרקה - peginterferon beta 1a 94 mcg / 0.5 ml - peginterferon beta-1a

דיפרוג'נטה קרם ישראל - עברית - Ministry of Health

דיפרוג'נטה קרם

organon pharma israel ltd., israel - betamethasone as dipropionate; gentamicin (as sulfate) - קרם - gentamicin (as sulfate) 1 mg/g; betamethasone as dipropionate 0.5 mg/g - corticosteroids, potent, combinations with antibiotics - for the relief of the inflammatory manifestations of corticosteroid-responsive dermatoses when complicated by secondary infections caused by organisms susceptible to gentamycin.

טרידרם קרם ישראל - עברית - Ministry of Health

טרידרם קרם

organon pharma israel ltd., israel - betamethasone as dipropionate; clotrimazole; gentamicin (as sulfate) - קרם - clotrimazole 10 mg/g; betamethasone as dipropionate 0.5 mg/g; gentamicin (as sulfate) 1 mg/g - corticosteroids, potent, other combinations - treatment of corticosteroid-responsive dermatoses when complicated by infections caused by bacteria (sensitive to gentamicin) and fungi (sensitive to clotrimazole) or when the possibility of such infections is suspected. the cream is suitable for the use of oozing eczema.

דיפרוסאליק תרחיץ ישראל - עברית - Ministry of Health

דיפרוסאליק תרחיץ

organon pharma israel ltd., israel - betamethasone as dipropionate; salicylic acid - תרחיץ - salicylic acid 20 mg/g; betamethasone as dipropionate 0.5 mg/g - corticosteroids, potent, other combinations - provides anti-inflammatory, antipruritic, anti-allergic and keratinolytic activity in the topical management of subacute and chronic hyperkeratotic and dry dermatoses responsive to corticosteroid therapy

רביף 22 מקג ישראל - עברית - Ministry of Health

רביף 22 מקג

merck serono ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 44 mcg/ml - interferon beta-1a - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiple sclerosis has not been established.